AVIR
NASDAQ HealthcareAtea Pharmaceuticals, Inc. - common stock
Biotechnology
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
�� 市场数据
| 价格 | $5.74 |
|---|---|
| 成交量 | 418,853 |
| 市值 | 457.32M |
| 贝塔系数 | 0.160 |
| RSI（14日） | 68.7 |
| 200日均线 | $3.84 |
| 50日均线 | $5.28 |
| 52周最高 | $6.45 |
| 52周最低 | $2.46 |
| Forward P/E | -4.14 |
| Price / Book | 1.63 |
🎯 投资策略评分
AVIR 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 💰 Dividend Daddy (50/100) — 此策略 高股息率 + 低波动性.
评分最低的策略： 🚀 Moon Shot (11/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 AVIR in your text
粘贴任何文章、记录或帖子 — 工具将提取 AVIR 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-04-17.